credits bmbl December 7 '06.doc - Central Michigan University

More documents

Recommendations

Info

Agent Summary Statements – Viral Agents 60. Wright R, Johnson D, Neumann M, et al. Congenital lymphocytic choriomeningitis virus syndrome: a disease that mimics congenital toxoplasmosis or Cytomegalovirus infection. Pediatrics. 1997;100:E9. 61. Dowdle WR, Gary HE, Sanders R, et al. Can post-eradication laboratory containment of wild polioviruses be achieved? Bull World Health Organ. 2002;80:311-6. 62. Mulders MN, Reimerink JHJ, Koopmans MPG, et al. Genetic analysis of wild type poliovirus importation into The Netherlands (1979-1995). J Infect Dis. 1997;176:617-24. 63. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). 2002;49(RR-5):1-22. 64. Uirusu. WHO global action plan for laboratory containment of wild poliovirus. 2nd ed. 2005;55:161-78. 65. Esposito JJ, Fenner F. Poxviruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields virology. 4 th ed. Philadelphia: Lippincott, Williams and Wilkins, Philadelphia. 2002. p. 2885-921. 66. Lewis-Jones S. Zoonotic poxvirus infections in humans. Curr Opin Infect Dis. 2004;17:81-9. 67. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350:342-50. 68. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-7):1-16. 69. Centers for Disease Control and Prevention. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2003;52:282-4. 70. Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Morb Mortal Wkly Rep. 2001;50(RR-10):1-25. 71. NIH Guidelines for Research Involving Recombinant DNA Molecules. Bethesda: The National Institutes of Health (US), Office of Biotechnology Activities; 2002, April. 72. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002;2:327-43. 73. Winkler WG, Fashinell TR, Leffingwell L, et al. Airborne rabies transmission in a laboratory worker. JAMA. 1973;226:1219-21. 74. Centers for Disease Control and Prevention. Rabies in a laboratory worker, New York. MMWR Morb Mortal Wkly Rep. 1977;26:183-4. 75. Centers for Disease Control and Prevention. Human rabies prevention-United States, 1999. MMWR Morb Mortal Wkly Rep. 1999;48(RR-1):1-29. 76. Rupprecht CE, Gibbons RV. Prophylaxis against rabies. New Engl J Med. 2004;351: 2626-35. 242
Agent Summary Statements – Viral Agents 77. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, June 1998. Atlanta, GA; 1998. 78. Khabbaz RF, Rowe T, Murphey-Corb M, et al. Simian immunodeficiency virus needlestick accident in a laboratory worker. Lancet. 1992;340:271-3. 79. Centers for Disease Control and Prevention. Seroconversion to simian immunodeficiency virus in two laboratory workers. MMWR Morb Mortal Wkly Rep. 1992;41:678-81. 80. Sotir M, Switzer W, Schable C, et al. Risk of occupational exposure to potentially infectious nonhuman primate materials and to simian immunodeficiency virus. J Med Primatol. 1997;26:233-40. 81. Schochetman G, George JR. AIDS testing: methodology and management issues. New York: Springer-Verlag; 1991. 82. Centers for Disease Control and Prevention. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other bloodborne pathogens in healthcare settings. MMWR Morb Mortal Wkly Rep. 1988; 37:377-82, 387, 388. 83. Occupational exposure to bloodborne pathogens. Final Rule. Fed. Register 1991;56:64175-82. 84. Center for Disease Control, Taiwan. [www.cdc.gov.tw]. A Report on the Laboratory-Acquired SARS Case in Taiwan [cited 2004 Jan 7]. [about one screen]. Available from: http://www.cdc.gov.tw/sarsen/ 85. Singapore Ministry of Health. [www.moh.gov]. Singapore: Singapore Ministry of Health. Biosafety and SARS Incident in Singapore, September 2003. Report of the review panel on new SARS case and biosafety; [about 31 screens]. Available from: http://www.moh.gov.sg/sars/pdf/Report_SARS_Biosafety.pdf 86. Centers for Disease Control and Prevention. [www.cdc.gov]. Atlanta, GA; [updated 2004 May 19]. Severe Acute Respiratory Syndrome (SARS); [about one screen]. Available from: http://www.cdc.gov/ncidod/sars/situation/may19.htm 87. Severe acute respiratory syndrome. In: Heymann, D, editor. Control of communicable diseases. 18 th ed. Washington, DC: America Public Health Association. 2004. p. 480-487. 88. Chow PK, Ooi, EE, Tan, HK, et al. Healthcare worker seroconversion in SARS outbreak. Emerg Infect Dis. 2004;10:225-31. 89. Loeb M, McGeer A, Henry B, et al. SARS among critical care nurses, Toronto. Emerg Infect Dis. 2004;10:251-5. 90. Centers for Disease Control and Prevention. [www.cdc.gov]. Atlanta, GA; [updated 2004 May 19]. Supplement F: Laboratory Guidance; [about two screens]. Available from: http://www.cdc.gov/ncidod/sars/guidance/f/index.htm 243
Page 1 and 2:
Biosafety in Microbiological and Bi
Page 3 and 4:
SECTION VIII-H: Prion Diseases 299
Page 5 and 6:
Forward Biosafety in Microbiologica
Page 7 and 8:
Editors: L. Casey Chosewood, MD Dir
Page 9 and 10:
Guest Editors: Matthew J. Arduino,
Page 11 and 12:
Charles B. Millard, PhD Lieutenant
Page 13 and 14:
Robert Bull Karen B. Byers Jane Cap
Page 15 and 16:
Thomas L. Miller Douglas M. Moore M
Page 17 and 18:
Robert Yarchoan Uri Yokel Lisa Youn
Page 19 and 20:
Introduction laboratories chose not
Page 21 and 22:
Introduction RISK CRITERIA FOR ESTA
Page 23 and 24:
Introduction BMBL includes an impor
Page 25 and 26:
Section II Biological Risk Assessme
Page 27 and 28:
Biological Risk Assessment informat
Page 29 and 30:
Biological Risk Assessment The NIH
Page 31 and 32:
Biological Risk Assessment effectiv
Page 33 and 34:
Biological Risk Assessment Third, m
Page 35 and 36:
Biological Risk Assessment 14. Oxma
Page 37 and 38:
Principles of Biosafety Safety equi
Page 39 and 40:
Principles of Biosafety Often an in
Page 41 and 42:
Principles of Biosafety Four standa
Page 43 and 44:
Principles of Biosafety 4. Centers
Page 45 and 46:
Laboratory Biosafety Level Criteria
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Section V Vertebrate Animal Biosafe
Page 77 and 78:
Vertebrate Animal Biosafety Level C
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
TABLE 1 SUMMARY OF RECOMMENDED BIOS
Page 121 and 122:
Principles of Laboratory Biosecurit
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Occupational Health and Immunoproph
Page 134 and 135:
Page 137 and 138:
Page 139 and 140:
Agent Summary Statements - Bacteria
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
• Section VIII-B: Fungal Agents A
Page 187 and 188:
Agent Summary Statements - Fungal A
Page 189 and 190:
Agent Summary Statements - Fungal A
Page 191 and 192: Agent Summary Statements - Fungal A
Page 197 and 198: • Section VIII-C: Parasitic Agent
Page 199 and 200: Agent Summary Statements - Parasiti
Page 209 and 210: • Section VIII-D: Rickettsial Age
Page 211 and 212: Agent Summary Statements - Ricketts
Page 213 and 214: Agent Summary Statements - Ricketts
Page 215 and 216: • Section VIII-E: Viral Agents Ag
Page 217 and 218: Agent Summary Statements - Viral Ag
Page 241: Agent Summary Statements - Viral Ag
Page 245 and 246: Agent Summary Statements - Arboviru
Page 285 and 286: • Section VIII-G: Toxin Agents Se
Page 287 and 288: Agent Summary Statements - Toxins i
Page 289 and 290: Agent Summary Statements - Toxins A
Page 291 and 292: Agent Summary Statements - Toxins L
Page 293 and 294:
Agent Summary Statements - Toxins e
Page 295 and 296:
Agent Summary Statements - Toxins o
Page 297 and 298:
Agent Summary Statements - Toxins t
Page 299 and 300:
• Section VIII-H: Prion Diseases
Page 301 and 302:
Agent Summary Statement - Prion Dis
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Appendix A Proper maintenance of ca
Page 309 and 310:
Appendix A declined. However, in ma
Page 311 and 312:
Appendix A It is possible to exhaus
Page 313 and 314:
Appendix A 4. The Class II, Type A2
Page 315 and 316:
Appendix A prohibited. Furthermore,
Page 317 and 318:
Appendix A plastic wrappers, pipett
Page 319 and 320:
Appendix A touch-plate microburners
Page 321 and 322:
Appendix A SECTION VI FACILITY AND
Page 323 and 324:
Appendix A Development of Containme
Page 325 and 326:
Appendix A C. Airflow Smoke Pattern
Page 327 and 328:
Appendix A TABLES Table 1. Selectio
Page 329 and 330:
Appendix A Table 3. Field Performan
Page 331 and 332:
Appendix A FIGURES Figure 1. HEPA f
Page 333 and 334:
Appendix A Figure 3. The Class II,
Page 335 and 336:
Appendix A Figure 5B. The Class II,
Page 337 and 338:
Appendix A Figure 8. The Class III
Page 339 and 340:
Appendix A Figure 9B. The vertical
Page 341 and 342:
Appendix A Figure 11. A typical lay
Page 343 and 344:
Appendix A REFERENCES 1. Centers fo
Page 345 and 346:
Appendix B Decontamination and Disi
Page 347 and 348:
Appendix B surfaces are contaminate
Page 349 and 350:
Appendix B TABLE 1 DESCENDING ORDER
Page 351 and 352:
Appendix B dioxide gas exits the ge
Page 353 and 354:
Appendix B d The effectiveness of a
Page 355 and 356:
Appendix C Transportation of Infect
Page 357 and 358:
Appendix C 1600 Clifton Road, N.E.,
Page 359 and 360:
Appendix C disease in humans or in
Page 361 and 362:
Appendix C Biological specimen, Cat
Page 363 and 364:
Appendix D Agriculture Pathogen Bio
Page 365 and 366:
Appendix D simultaneous opening of
Page 367 and 368:
Appendix D 14. Pathological inciner
Page 369 and 370:
Appendix D Wastes and other materia
Page 371 and 372:
Appendix D Camelpox virus b a, b, c
Page 373 and 374:
Appendix D SPECIAL ISSUES The impor
Page 375 and 376:
Appendix D required by the USDA and
Page 377 and 378:
Appendix D depression, anorexia, an
Page 379 and 380:
Appendix D laboratory with enhancem
Page 381 and 382:
Appendix D five day period of conta
Page 383 and 384:
Appendix D slaughterhouses or indus
Page 385 and 386:
Appendix D virus does not cause any
Page 387 and 388:
Appendix D NDV is classified in the
Page 389 and 390:
Appendix D movement permit is requi
Page 391 and 392:
Appendix D Spring Viremia of Carp V
Page 393 and 394:
Appendix D REFERENCES 1. Hess WR. A
Page 395 and 396:
Appendix D 37. Alexander DJ. Newcas
Page 397 and 398:
Appendix E Arthropod Containment Gu
Page 399 and 400:
Appendix F Select Agents and Toxins
Page 401 and 402:
Appendix G IPM issues and requireme
Page 403 and 404:
Appendix H Working with Human, NHP
Page 405 and 406:
Appendix I Guidelines for Work with
Page 407 and 408:
decontaminated periodically, for ex
Page 409 and 410:
0.25N, and/or sodium hypochlorite (
Page 411 and 412:
k Irradiation causes a dose-depende
Page 413 and 414:
7. Morin R, Kozlovac J. Biological
Page 415 and 416:
Appendix J NIH Oversight of Researc
Page 417 and 418:
Appendix K Resources for Informatio
Page 419 and 420:
Appendix K E-mail: http://www2.gsu.
Page 421 and 422:
Appendix K and http://www.who.int/c
Page 423 and 424:
Appendix L HEPA High Efficiency Par
show all

credits bmbl December 7 '06.doc - Central Michigan University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?